AL003 – SIGLEC 3 – Alzheimer’s disease
AL003 focuses on modulating check-point receptors on the brain’s immune cells, targeting sialic acid binding Ig-like lectin 3 (SIGLEC 3), a genetic risk factor for Alzheimer’s disease. SIGLEC 3 is an inhibitory receptor expressed primarily on cells of myeloid lineage including microglia. AL003 is intended to bock the function of SIGLEC3 to increase the activity of the microglia. The Phase 1b study of AL003 in 12 Alzheimer’s disease patients is intended to assess the safety and tolerability of multiple doses of AL003.
AL003 is being developed in collaboration with AbbVie.